Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8103460 | 0.90 | MAPT (0.46) | KMT2AATMSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL6924446 | 0.87 | RAB9A (0.46) | KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6565732 | 0.80 | HSD17B10 (0.47) | KMT2ASMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL6564201 | 0.80 | ELANE (0.52) | KMT2ASMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL57245 | 0.80 | KMT2A (0.50) | KMT2AATMCES2CES1SMN1; SMN2 | |
| SCHEMBL18697279 | 0.78 | KMT2A (0.46) | KMT2AATMCES2CES1SMN1; SMN2 | |
| SCHEMBL17434705 | 0.78 | KMT2A (0.46) | KMT2AATMCES2CES1SMN1; SMN2 | |
| SCHEMBL9578961 | 0.78 | MAPT (0.50) | KMT2AKDM4EALDH1A1HPGDCA1 | |
| SCHEMBL59462 | 0.78 | ELANE (0.48) | KMT2ACES2CES1SMN1; SMN2CYP1A2 | |
| SCHEMBL14389790 | 0.78 | KMT2A (0.46) | KMT2AATMCES2CES1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130395-A1 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-05-06 | — | — | US | claimed |
| WO-2019217900-A1 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-11-14 | — | — | WO | claimed |
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | claimed |
| EP-1315729-B1 | COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PROD QUIMICOS FARM (BR) | 2008-01-09 | — | — | EP | claimed |
| EP-1315729-A4 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PRODUTOS QUIMICOS E (BR) | 2004-07-07 | — | — | EP | claimed |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PACHECO, OGARI (BR) | 2004-06-03 | — | — | US | claimed |
| EP-1315729-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristalia Produtos Quimicos e Farmaceuticos Ltda (BR) | 2003-06-04 | — | — | EP | claimed |
| WO-2002012241-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristália Produtos Químicos e Farmacêuticos Ltda. (BR) | 2002-02-14 | — | — | WO | claimed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4673179-A1 | BONE-DIRECTED THERAPEUTICS FOR THE TREATMENT OF CANCER | William Marsh Rice University (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| EP-4654968-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | Alivus Life Sciences Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-5231107-A | Compounds for treatment of Alzheimer*s disease or memory defects | ROUSSEL UCLAF (FR) | 1993-07-27 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| US-5140041-A | Cognition activators, for treatment of Alzheimer's disease | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-08-18 | — | — | US | disclosed |
| EP-0443474-A2 | 1-Phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4003909-A | [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3986973-A | CYANOFORMATES AND CYANOFORMAMIDES AS BLEACH ACTIVATORS | AMERICAN CYANAMID COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | KMT2A 3647/4885ATM 4778/4885CES2 87/4885 |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PEPD, PREP, PAPSS1 | KMT2A 4493/4885ATM 4290/4885CES2 10/4885 |
| US-20210130395-A1 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | CD2BP2, FCGR2A, FCGR3B | KMT2A 2673/4885ATM 2552/4885CES2 2247/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | KMT2A 2287/4885ATM 4122/4885CES2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.